Clinical Trial Update: Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration [Phase 1]

View source ↗

Summary

A completed Phase 1 safety study assessed NNZ-2566 in healthy volunteers after oral dosing. The study evaluated safety and tolerability in individuals without T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• NNZ-2566

Snippet

Sponsor: Neuren Pharmaceuticals Limited | Conditions: Brain Injuries, Traumatic | Phase 1 | Status: COMPLETED